Compositions and methods for preventing and treating coronavirus infection—SARS-CoV-2 vaccines
The invention relates to immunogenic compositions and vaccines containing a coronavirus (e.g., Wuhan coronavirus (2019-nCoV; also referred to as SARS-CoV-2)) protein or a polynucleotide encoding a coronavirus (e.g., Wuhan coronavirus (2019-nCoV; SARS-CoV-2)) protein and uses thereof. The invention also provides methods of treating and/or preventing a coronavirus (e.g., Wuhan coronavirus (2019-nCoV; SARS-CoV-2)) infection by administering an immunogenic composition or vaccine to a subject (e.g., a human). The invention also provides methods of detecting and/or monitoring a protective anti-coronavirus (e.g., Wuhan coronavirus (2019-nCoV; SARS-CoV-2)) antibody response (e.g., anti-coronavirus antibody response, e.g., anti-2019-nCoV antibody response, e.g., anti-Spike antibody response, e.g., anti-Spike neutralizing antibody response). The present invention relates to isolated nucleic and/or recombinant nucleic acid encoding a coronavirus S protein, in particular a SARS-CoV-2 S protein, and to the coronavirus S proteins, as well as to the use of the nucleic acids and/or proteins thereof in vaccines.
1. An isolated nucleic acid encoding a polypeptide comprising a modified coronavirus Spike (S) protein, wherein the polypeptide comprises amino acids residues 14-1273 of SEQ ID NO: 205.
2. The isolated nucleic acid according to claim 1 , wherein the polypeptide comprises the amino sequence of SEQ ID NO: 205.
3. The isolated nucleic acid according to claim 1 , wherein the polypeptide comprises the amino sequence of SEQ ID NO: 208.
4. The isolated nucleic acid according to claim 1 , wherein the isolated nucleic acid comprises a nucleotide sequence at least 90% identical to SEQ ID NO:211, or SEQ ID NO: 214.
5. A vector comprising the nucleic acid according to claim 1 .
6. The vector according to claim 5 , wherein the vector is a recombinant adenovirus vector.
7. The vector according to claim 6 , wherein the recombinant adenovirus vector has a deletion in the E1 region, a deletion in the E3 region, or a deletion in both the E1 region and the E3 region of the adenoviral genome.
8. The vector according to claim 5 , wherein the nucleic acid encoding the polypeptide comprising the modified coronavirus S protein is operably linked to a cytomegalovirus (CMV) promoter comprising at least one tetracycline operator (TetO) motif.
9. The vector of claim 8 , wherein the nucleic acid encoding the polypeptide comprising the modified coronavirus S protein is operably linked to the CMV promoter having the nucleotide sequence of SEQ ID NO: 219.
10. A recombinant human adenovirus vector of serotype 26 comprising a nucleic acid encoding a polypeptide comprising a modified coronavirus Spike (S) protein, wherein the recombinant human adenovirus has a deletion in the E1 region, a deletion in the E3 region, or a deletion in both the E1 and the E3 region of the adenoviral genome, the nucleic acid encoding the polypeptide comprising the modified coronavirus S protein is operably linked to a cytomegalovirus (CMV) promoter comprising the nucleotide sequence of SEQ ID NO: 219, and the polypeptide comprises amino acids residues 14-1273 of SEQ ID NO: 205.
11. The recombinant human adenovirus vector of serotype 26 according to claim 10 , wherein the polypeptide comprises the amino sequence of SEQ ID NO: 205.
12. The recombinant human adenovirus vector of serotype 26 according to claim 10 , wherein the polypeptide comprises the amino sequence of SEQ ID NO: 208.
13. The recombinant human adenovirus vector of serotype 26 according to claim 10 , wherein the isolated nucleic acid comprises the nucleotide sequence of SEQ ID NO:211.
14. The recombinant human adenovirus vector of serotype 26 according to claim 10 , wherein the isolated nucleic acid comprises the nucleotide sequence of SEQ ID NO:214.
15. A recombinant vector comprising the polynucleotide sequence of SEQ ID NO: 218 and the polynucleotide sequence of SEQ ID NO: 211 or SEQ ID NO: 214.
16. A pharmaceutical composition comprising the nucleic acid according to claim 1 and a pharmaceutically acceptable carrier.
17. A pharmaceutical composition comprising the vector according to claim 5 and a pharmaceutically acceptable carrier.
18. A pharmaceutical composition comprising the vector according to claim 10 and a pharmaceutically acceptable carrier.
19. A pharmaceutical composition comprising the vector according to claim 15 and a pharmaceutically acceptable carrier.
20. An isolated host cell comprising the nucleic acid according to claim 1 .
21. An isolated host cell comprising the vector according to claim 5 .
22. An isolated host cell comprising the vector according to claim 15 .
23. A method of producing the vector of claim 5 , comprising growing a host cell comprising the vector under conditions for the production of the vector.
24. A method of manufacturing a pharmaceutical composition, the method comprising:
(a) admixing the nucleic acid of claim 1 or a vector comprising the nucleic acid of claim 1 with a pharmaceutically acceptable carrier to form the pharmaceutical composition; and
(b) placing the pharmaceutical composition in a container.
25. A method of inducing an immune response in a subject in need thereof, comprising administering to the subject the pharmaceutical composition of claim 16 .
26. A method of inducing an immune response in a subject in need thereof, comprising administering to the subject the pharmaceutical composition of claim 17 .
27. A method of inducing an immune response in a subject in need thereof, comprising administering to the subject the pharmaceutical composition of claim 19 .
28. A method for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in a subject 18 years of age and older, the method comprising administering to the subject the pharmaceutical composition according to claim 16 .
29. A method for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in a subject 18 years of age and older, the method comprising administering to the subject the pharmaceutical composition according to claim 17 .
30. A method for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in a subject 18 years of age and older, the method comprising administering to the subject the pharmaceutical composition according to claim 19 .